ADCC, or antibody-dependent cellular cytotoxicity, is a mechanism your immune system uses to kill infected or abnormal cells. It works by combining two forces: antibodies that flag a target cell and immune cells that destroy it. Think of antibodies as spotters that physically grab onto a threat and wave down the demolition crew. This process is central to how the body fights viral infections and cancer, and it’s also the key mechanism behind several widely used cancer drugs.
How ADCC Works, Step by Step
The process begins when antibodies (specifically IgG, the most common type in your blood) latch onto a protein on the surface of a target cell. This could be a virus-infected cell displaying viral proteins, or a cancer cell displaying abnormal ones. The antibody grabs the target with one end (its antigen-binding fragment) while its other end (the Fc region) sticks outward like a flag, ready to be recognized by immune cells.
Natural killer (NK) cells are the primary responders. They carry a surface receptor called CD16a that locks onto the exposed Fc region of the antibody. When enough antibodies cluster on a target, multiple CD16a receptors on the NK cell engage simultaneously, triggering activation. The NK cell then releases tiny packets of toxic chemicals directly at the target. Two proteins do most of the killing: perforins punch holes in the target cell’s membrane, and granzyme B slips through those holes and triggers the cell’s self-destruct program (apoptosis), fragmenting its DNA. NK cells can also activate a backup killing pathway by displaying a molecule called Fas ligand, which triggers death in target cells carrying the matching Fas receptor.
The entire process is contact-dependent. The NK cell forms a tight junction with the target, aims its toxic granules precisely, and releases them in a calcium-dependent burst. This keeps the damage focused on the flagged cell rather than harming surrounding tissue.
Which Immune Cells Can Perform ADCC
NK cells get the most attention, but they aren’t the only effector cells involved. Macrophages and neutrophils also carry Fc receptors and can participate in ADCC. In fact, studies suggest that macrophages may be the primary effectors for some therapeutic antibodies in living tissue, even though lab tests traditionally measure only NK cell activity. The difference is practical: NK cells circulate freely in the blood and are easy to isolate, while macrophages reside in tissues and require a week of specialized culturing to study outside the body. This has historically biased research toward NK cells, but the picture of ADCC in real immune responses is broader than any single cell type.
What Controls How Strong the Response Is
Your body doesn’t leave ADCC running unchecked. Immune cells carry both activating and inhibitory Fc receptors, and the balance between them determines whether killing proceeds. Activating receptors contain signaling motifs (ITAMs) that green-light the attack. Inhibitory receptors, particularly one called FcγRIIb, contain the opposite type of motif (ITIMs) that dampen immune activation. The inhibitory receptor binds antibodies with roughly 40 times lower affinity than some activating receptors, which means the system is tilted toward action when antibodies are abundant on a target, but can still pump the brakes when the signal is weak or ambiguous.
Not all antibody types trigger ADCC equally. Of the four IgG subclasses in humans, IgG1 and IgG3 bind strongly to CD16a and are potent ADCC inducers. IgG2 and IgG4 bind weakly or not at all, making them essentially inactive for this purpose. This is why nearly all therapeutic antibodies designed to harness ADCC use an IgG1 backbone.
Genetic Variation in ADCC Strength
A well-studied genetic difference in the CD16a receptor gene affects how tightly it grips antibodies. People can carry either a valine (V) or phenylalanine (F) at position 158 of the receptor. The valine version binds antibodies more tightly and produces stronger ADCC. This isn’t just a lab curiosity: individuals carrying at least one valine copy show better responses to rituximab, a cancer-targeting antibody, in clinical studies. This polymorphism alters the receptor’s shape just enough to change its grip on the antibody’s Fc region, and it helps explain why patients receiving the same drug can have different outcomes.
How ADCC Differs From Complement Killing
ADCC is sometimes confused with complement-dependent cytotoxicity (CDC), another antibody-driven killing mechanism. The distinction is straightforward: ADCC recruits living immune cells to do the killing, while CDC activates a cascade of proteins (the complement system) that directly punch holes in the target cell’s membrane without any cellular involvement. CDC requires a high density of target proteins on the cell surface, which tumor cells rarely provide, so antibodies in cancer therapy typically rely more heavily on ADCC. Some therapeutic antibodies can trigger both pathways, but ADCC is generally considered the more reliable and well-proven mechanism for tumor clearance.
ADCC in Cancer Therapy
Several of the most successful cancer drugs work, at least in part, through ADCC. Trastuzumab targets the HER2 protein on breast cancer cells and has been a first-line treatment for HER2-positive breast cancer for over two decades. Rituximab targets a protein called CD20 on B-cell lymphomas. Cetuximab targets a growth factor receptor found on colorectal and head-and-neck cancers. In each case, the drug coats cancer cells with antibodies, turning them into targets for NK cells and other ADCC-capable immune cells.
Newer antibody-drug conjugates build on this foundation. Drugs like trastuzumab-emtansine and trastuzumab-deruxtecan attach a toxic chemical payload to the antibody. When the antibody binds the cancer cell, the payload gets pulled inside and poisons the cell directly. Importantly, these conjugates still retain the ability to trigger ADCC, combining direct poisoning with immune-mediated killing for a two-pronged attack.
Because ADCC is so central to these therapies, drug developers actively engineer antibodies to enhance it. One common approach involves modifying sugar molecules attached to the antibody’s Fc region. Removing a specific sugar called fucose from that region increases binding to CD16a and boosts ADCC activity regardless of IgG subclass. This kind of Fc engineering has become a standard strategy in designing next-generation cancer antibodies.
How ADCC Is Measured in the Lab
The traditional method for measuring ADCC is the chromium-51 release assay, long considered the gold standard. Target cells are loaded with radioactive chromium, mixed with antibodies and effector cells, and when target cells are killed, they release chromium into the surrounding fluid, which is then measured. Higher radioactivity means more killing. This assay is reliable and sensitive but involves handling radioactive materials, which has pushed researchers toward alternatives.
Newer approaches include fluorescence-based assays that label target cells with dyes, and reporter-cell assays that use engineered Jurkat cells (a type of immune cell line) carrying CD16a and a luminescent reporter gene. When the reporter cells engage antibody-coated targets, they produce light proportional to activation. These surrogate assays are simpler and scalable, which makes them particularly useful for screening therapeutic antibodies during drug development, though they measure activation rather than actual cell killing.